Advaxis Inc (ADXS) 11.90 $ADXS
Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference
GlobeNewswire - Mon Mar 02, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the Cowen and Company 35th Annual Health Care Conference being held March 2-4, 2015, at the Boston Marriott Copley Place in Boston, MA.
ADXS: 11.90 (+0.80)
First Week of ADXS October 16th Options Trading
StockOptionsChannel.com - Fri Feb 27, 9:44AM CST
Investors in Advaxis, Inc. saw new options become available this week, for the October 16th expiration.
ADXS: 11.90 (+0.80)
5 Stocks Insiders Love Right Now: GE, Mondelez and More
at The Street - Wed Feb 25, 6:00AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
GE: 25.42 (-0.40), ADXS: 11.90 (+0.80), MDLZ: 35.22 (-1.29), MDGN: 8.35 (+0.17), MDAS: 18.44 (+0.11)
InsiderInsights.com Daily Round Up 2/20/15: GPRO, WMS, TNGO, SONS
InsiderInsights - at Seeking Alpha - Sat Feb 21, 11:18PM CST
TNGO: 12.29 (-0.21), GPRO: 40.13 (-0.95), ADXS: 11.90 (+0.80), GE: 25.42 (-0.40), PNNT: 9.77 (+0.02), SONS: 15.75 (-0.33), WMS: 27.80 (+0.04), JOB: 1.00 (+0.04), BMS: 47.41 (-0.42), GOOG: 567.68 (-7.65), MAS: 25.97 (-0.86), ENT: 13.14 (-0.36), MXWL: 7.23 (-0.44), MSG: 76.05 (-0.94), TSRA: 39.92 (+0.26), CUDA: 38.45 (-0.16), THLD: 4.45 (-0.11), SIX: 45.97 (-0.79), TWTR: 46.75 (-0.60), DATA: 92.34 (-3.16)
Advaxis Surges Higher on Additional Institutional Interest
at The Street - Thu Feb 19, 8:15AM CST
Advaxis stock rallied after a private placement showed added fund participation. Read how this move has rebutted the short thesis.
ADXS: 11.90 (+0.80)
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 18, 5:30PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TTS: 10.82 (-0.13), KNDI: 13.40 (-0.29), ADXS: 11.90 (+0.80), BRDR: 7.34 (-0.20), NERV: 5.34 (-0.24), ANGI: 6.80 (+0.08), SRPT: 13.63 (-0.45), GWGH: 8.18 (+0.18), EGRX: 37.63 (-0.37), Z: 112.52 (-1.95)
Advaxis completes $23M financing
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 12:00PM CST
ADXS: 11.90 (+0.80)
Advaxis Completes $23 Million Financing
GlobeNewswire - Wed Feb 18, 11:15AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that it has executed definitive securities purchase agreements with several institutional investors for gross proceeds of approximately $23.0 million in a registered direct offering of approximately 3.1 million shares at a price of $7.50 per share. The pricing on this transaction reflects the at-the-market closing price on February 17, 2015.
ADXS: 11.90 (+0.80)
Advaxis Appoints Mayo Pujols Vice President, Manufacturing
GlobeNewswire - Fri Feb 13, 9:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo Pujols as Vice President, Manufacturing. Mr. Pujols brings to Advaxis more than 22 years of experience in global commercial and clinical manufacturing, technology transfer, and product development strategy.
ADXS: 11.90 (+0.80), MRK: 56.84 (-1.14)
Advaxis teams up with Incyte in cervical cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:47AM CST
ADXS: 11.90 (+0.80), INCY: 90.00 (-1.97)
Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
GlobeNewswire - Wed Feb 11, 9:55AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
ADXS: 11.90 (+0.80), INCY: 90.00 (-1.97)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:13AM CST
FCEL: 1.41 (+0.09), ADXS: 11.90 (+0.80), JONE: 8.68 (+0.26), INXN: 29.87 (-0.21), SDRL: 10.55 (-0.39), NBG: 1.43 (-0.08), GNW: 7.67 (+0.06), WBAI: 14.50 (+0.70), PME: 2.52 (-0.03), RAD: 7.65 (-0.03), BLDP: 2.29 (-0.06), BXE: 2.99 (-0.06), PXD: 156.17 (-4.27), ACHN: 11.39 (+0.40), SDR: 4.55 (-0.01), LGF: 32.75 (-0.76), PIR: 11.96 (-0.09), AOL: 40.80 (+0.25), GNRC: 49.14 (-0.56), GOL: 2.99 (-0.12), DCTH: 1.16 (+0.02), CHS: 17.50 (-0.23)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 11.90 (+0.80), ZIOP: 13.38 (-0.43), NPSP: 45.97 (+0.01), AMGN: 154.88 (-4.72), ARNA: 4.32 (+0.09)
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
at The Street - Fri Feb 06, 5:05AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 113.14 (+0.91), ADXS: 11.90 (+0.80), GILD: 101.81 (-1.61), HEB: 0.25 (-0.01), ACHN: 11.39 (+0.40), MRK: 56.84 (-1.14), ABBV: 55.64 (-1.22)
Lifshitz & Miller Law Firm Announces Investigation of Advanced Photonix, Inc., Advaxis, Inc., Advent Software, Inc., Books-A-Million, Inc., City National Corporation, Energy Recovery, Inc., and NetScout Systems, Inc.
PR Newswire - Wed Feb 04, 9:46AM CST
Advanced Photonix, Inc.
BAMM: 2.62 (+0.06), API: 0.41 (+0.01), LUNA: 1.38 (-0.07), ADXS: 11.90 (+0.80), NTCT: 41.82 (-0.15), ADVS: 44.05 (-0.07), CYN: 89.25 (-0.36), ERII: 2.79 (-0.47)
MarketExclusive.com - H.C. Wainwright & Co. Reiterates BUY Rating of Advaxis Inc. and Reports Encouraging Updates on ADXS-HPV Programs
ACCESSWIRE - Wed Feb 04, 9:44AM CST
New York, NY / ACCESSWIRE / February 4, 2015 / Market Exclusive announces that H.C. Wainwright & Co has reported on encouraging updates on Advaxis Inc.'s (Nasdaq:ADXS) ADXS-HPV programs presented at the company's investor day on February 3, 2015. H.C. Wainwright & Co. continues to rate the shares of Advaxis as Buy with a 12-month price target of $14.00 per share.
ADXS: 11.90 (+0.80)
Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference
GlobeNewswire - Mon Mar 02, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the Cowen and Company 35th Annual Health Care Conference being held March 2-4, 2015, at the Boston Marriott Copley Place in Boston, MA.
ADXS: 11.90 (+0.80)
First Week of ADXS October 16th Options Trading
StockOptionsChannel.com - Fri Feb 27, 9:44AM CST
Investors in Advaxis, Inc. saw new options become available this week, for the October 16th expiration.
ADXS: 11.90 (+0.80)
5 Stocks Insiders Love Right Now: GE, Mondelez and More
at The Street - Wed Feb 25, 6:00AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
GE: 25.42 (-0.40), ADXS: 11.90 (+0.80), MDLZ: 35.22 (-1.29), MDGN: 8.35 (+0.17), MDAS: 18.44 (+0.11)
InsiderInsights.com Daily Round Up 2/20/15: GPRO, WMS, TNGO, SONS
InsiderInsights - at Seeking Alpha - Sat Feb 21, 11:18PM CST
TNGO: 12.29 (-0.21), GPRO: 40.13 (-0.95), ADXS: 11.90 (+0.80), GE: 25.42 (-0.40), PNNT: 9.77 (+0.02), SONS: 15.75 (-0.33), WMS: 27.80 (+0.04), JOB: 1.00 (+0.04), BMS: 47.41 (-0.42), GOOG: 567.68 (-7.65), MAS: 25.97 (-0.86), ENT: 13.14 (-0.36), MXWL: 7.23 (-0.44), MSG: 76.05 (-0.94), TSRA: 39.92 (+0.26), CUDA: 38.45 (-0.16), THLD: 4.45 (-0.11), SIX: 45.97 (-0.79), TWTR: 46.75 (-0.60), DATA: 92.34 (-3.16)
Advaxis Surges Higher on Additional Institutional Interest
at The Street - Thu Feb 19, 8:15AM CST
Advaxis stock rallied after a private placement showed added fund participation. Read how this move has rebutted the short thesis.
ADXS: 11.90 (+0.80)
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 18, 5:30PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TTS: 10.82 (-0.13), KNDI: 13.40 (-0.29), ADXS: 11.90 (+0.80), BRDR: 7.34 (-0.20), NERV: 5.34 (-0.24), ANGI: 6.80 (+0.08), SRPT: 13.63 (-0.45), GWGH: 8.18 (+0.18), EGRX: 37.63 (-0.37), Z: 112.52 (-1.95)
Advaxis completes $23M financing
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 12:00PM CST
ADXS: 11.90 (+0.80)
Advaxis Completes $23 Million Financing
GlobeNewswire - Wed Feb 18, 11:15AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that it has executed definitive securities purchase agreements with several institutional investors for gross proceeds of approximately $23.0 million in a registered direct offering of approximately 3.1 million shares at a price of $7.50 per share. The pricing on this transaction reflects the at-the-market closing price on February 17, 2015.
ADXS: 11.90 (+0.80)
Advaxis Appoints Mayo Pujols Vice President, Manufacturing
GlobeNewswire - Fri Feb 13, 9:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo Pujols as Vice President, Manufacturing. Mr. Pujols brings to Advaxis more than 22 years of experience in global commercial and clinical manufacturing, technology transfer, and product development strategy.
ADXS: 11.90 (+0.80), MRK: 56.84 (-1.14)
Advaxis teams up with Incyte in cervical cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:47AM CST
ADXS: 11.90 (+0.80), INCY: 90.00 (-1.97)
Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
GlobeNewswire - Wed Feb 11, 9:55AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
ADXS: 11.90 (+0.80), INCY: 90.00 (-1.97)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:13AM CST
FCEL: 1.41 (+0.09), ADXS: 11.90 (+0.80), JONE: 8.68 (+0.26), INXN: 29.87 (-0.21), SDRL: 10.55 (-0.39), NBG: 1.43 (-0.08), GNW: 7.67 (+0.06), WBAI: 14.50 (+0.70), PME: 2.52 (-0.03), RAD: 7.65 (-0.03), BLDP: 2.29 (-0.06), BXE: 2.99 (-0.06), PXD: 156.17 (-4.27), ACHN: 11.39 (+0.40), SDR: 4.55 (-0.01), LGF: 32.75 (-0.76), PIR: 11.96 (-0.09), AOL: 40.80 (+0.25), GNRC: 49.14 (-0.56), GOL: 2.99 (-0.12), DCTH: 1.16 (+0.02), CHS: 17.50 (-0.23)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 11.90 (+0.80), ZIOP: 13.38 (-0.43), NPSP: 45.97 (+0.01), AMGN: 154.88 (-4.72), ARNA: 4.32 (+0.09)
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
at The Street - Fri Feb 06, 5:05AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 113.14 (+0.91), ADXS: 11.90 (+0.80), GILD: 101.81 (-1.61), HEB: 0.25 (-0.01), ACHN: 11.39 (+0.40), MRK: 56.84 (-1.14), ABBV: 55.64 (-1.22)
Lifshitz & Miller Law Firm Announces Investigation of Advanced Photonix, Inc., Advaxis, Inc., Advent Software, Inc., Books-A-Million, Inc., City National Corporation, Energy Recovery, Inc., and NetScout Systems, Inc.
PR Newswire - Wed Feb 04, 9:46AM CST
Advanced Photonix, Inc.
BAMM: 2.62 (+0.06), API: 0.41 (+0.01), LUNA: 1.38 (-0.07), ADXS: 11.90 (+0.80), NTCT: 41.82 (-0.15), ADVS: 44.05 (-0.07), CYN: 89.25 (-0.36), ERII: 2.79 (-0.47)
MarketExclusive.com - H.C. Wainwright & Co. Reiterates BUY Rating of Advaxis Inc. and Reports Encouraging Updates on ADXS-HPV Programs
ACCESSWIRE - Wed Feb 04, 9:44AM CST
New York, NY / ACCESSWIRE / February 4, 2015 / Market Exclusive announces that H.C. Wainwright & Co has reported on encouraging updates on Advaxis Inc.'s (Nasdaq:ADXS) ADXS-HPV programs presented at the company's investor day on February 3, 2015. H.C. Wainwright & Co. continues to rate the shares of Advaxis as Buy with a 12-month price target of $14.00 per share.
ADXS: 11.90 (+0.80)
